Page:United States Statutes at Large Volume 124.djvu/542

 124 STAT. 516 PUBLIC LAW 111–148—MAR. 23, 2010 SEC. 3503. MEDICATION MANAGEMENT SERVICES IN TREATMENT OF CHRONIC DISEASE. Title IX of the Public Health Service Act (42 U.S.C. 299 et seq.), as amended by section 3501, is further amended by inserting after section 934 the following: ‘‘SEC. 935. GRANTS OR CONTRACTS TO IMPLEMENT MEDICATION MANAGEMENT SERVICES IN TREATMENT OF CHRONIC DISEASES. ‘‘(a) IN GENERAL.—The Secretary, acting through the Patient Safety Research Center established in section 933 (referred to in this section as the ‘Center’), shall establish a program to provide grants or contracts to eligible entities to implement medication management (referred to in this section as ‘MTM’) services provided by licensed pharmacists, as a collaborative, multidisciplinary, inter- professional approach to the treatment of chronic diseases for tar- geted individuals, to improve the quality of care and reduce overall cost in the treatment of such diseases. The Secretary shall com- mence the program under this section not later than May 1, 2010. ‘‘(b) ELIGIBLE ENTITIES.—To be eligible to receive a grant or contract under subsection (a), an entity shall— ‘‘(1) provide a setting appropriate for MTM services, as recommended by the experts described in subsection (e); ‘‘(2) submit to the Secretary a plan for achieving long- term financial sustainability; ‘‘(3) where applicable, submit a plan for coordinating MTM services through local community health teams established in section 3502 of the Patient Protection and Affordable Care Act or in collaboration with primary care extension programs established in section 399W; ‘‘(4) submit a plan for meeting the requirements under subsection (c); and ‘‘(5) submit to the Secretary such other information as the Secretary may require. ‘‘(c) MTM SERVICES TO TARGETED INDIVIDUALS.—The MTM services provided with the assistance of a grant or contract awarded under subsection (a) shall, as allowed by State law including applicable collaborative pharmacy practice agreements, include— ‘‘(1) performing or obtaining necessary assessments of the health and functional status of each patient receiving such MTM services; ‘‘(2) formulating a medication treatment plan according to therapeutic goals agreed upon by the prescriber and the patient or caregiver or authorized representative of the patient; ‘‘(3) selecting, initiating, modifying, recommending changes to, or administering medication therapy; ‘‘(4) monitoring, which may include access to, ordering, or performing laboratory assessments, and evaluating the response of the patient to therapy, including safety and effectiveness; ‘‘(5) performing an initial comprehensive medication review to identify, resolve, and prevent medication-related problems, including adverse drug events, quarterly targeted medication reviews for ongoing monitoring, and additional followup inter- ventions on a schedule developed collaboratively with the pre- scriber; Plans. Deadline. 42 USC 299b–35.